sintilimab sold brand tyvyt among others medication used treat hodgkins approved fully human monoclonal binds programmed cell death protein jointly developed innovent eli sintilimab medication indicated treatment relapsed refractory classical hodgkins failure least secondline systemic common side effects include fever thyroid dysfunction elevation liver enzymes lung currently clinical trials ongoing evaluate antitumor effect sintilimab injection either monotherapy combination agents variety solid january result registration trial sintilimab people refractory relapsed classical hodgkins lymphoma httpsenwikipediaorgwikisintilimab